

JUN - 4 1997

K964660

510 (k) Summary of Safety and Effectiveness
Information

The Paramax® Cholesterol Reagent is substantially equivalent to DuPont aca Cholesterol Reagent, which was cleared to market on unknown. The proposed and the predicate device are intended for use in the quantitative determination of Cholesterol and HDL Cholesterol.

The Paramax® Cholesterol Reagent and DuPont aca Cholesterol Reagent are based on colorimetric methodology.

The technological characteristics of the predicate device are similar to those previously described for the proposed device.

The correlation between the Paramax® Cholesterol Reagent and DuPont aca Cholesterol Reagent was demonstrated by assaying 48 specimens using the Paramax® and DuPont aca Systems. The correlation coefficient for Cholesterol was 0.984, and the regression equation was $\text{Paramax}^{\circledR} \text{ value} = (1.10 * \text{aca value}) - 7.1$. For the HDLC, 100 specimens using Paramax® and DuPont aca Systems yielded a correlation coefficient of 0.9881 and a regression equation of $\text{Paramax}^{\circledR} \text{ value} = (1.012 * \text{aca value}) - 2.27$. The data indicates that the results obtained by both reagents are substantially equivalent.



Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

JUN - 4 1997

Marilyn S. Waxburg
• Director
Regulatory Affairs
Dade International, Inc.
9750 N.W. 25th Street
Miami, FL 33172

Re: K964660/S001
Paramax® Cholesterol Reagent
Regulatory Class: I
Product Code: CHH
Dated: March 20, 1997
Received: March 21, 1997

Dear Ms. Waxburg:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General (GMP) regulation (21 CFR Part 820) and that, through periodic GMP inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.


Page 2

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,



Steven I. Gutman, M.D., M.B.A.
Director
Division of Clinical
Laboratory Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

Statement of Indications for Use

510(k) Number (if known):

Device Name: Paramax® Cholesterol Reagent

Indication(s) for Use:

Intended Use

For quantitative determination of cholesterol or HDL cholesterol in plasma or serum. Cholesterol measurements are used in the diagnosis and treatment of disorders involving excess cholesterol in the blood and lipoprotein metabolism disorders¹.

PLEASE DO NOT WRITE BELOW THIS LINE (CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use XX
(Per 21 CFR 801.109)

OR Over-the-Counter Use

(Optional Format 1-2-96)



(Division Sign-Off)

Division of Clinical Laboratory Devices

510(k) Number K-964660